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Over the past decade, a keen interest has developed in the
imaging of atherosclerosis in patients in vivo. One approach
is the direct intracoronary visualization with ultrasound,
angioscopy, or more recently, magnetic resonance imaging
(MRI). Another, more practical approach is non-invasive
imaging with ultrasound, MRI, or radionuclide tracers. In
this issue of the Journal, Hamilton et al. (1) have reported
using the former approach in conjunction with liposomes
targeted to endothelial cell adhesion molecules and throm-
bus mediators in a model of aggravated vascular injury. This
study highlights both the potential and current limitations
of atherosclerosis imaging in vivo.
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Atherosclerosis starts with vascular injury, which initiates
a sequence of inflammatory responses that involve cellular
activation, migration, proliferation, and differentiation (2).
These events lead to plaque formation, vascular remodeling,
and eventually plaque encroachment into the vascular lumen
and resulting luminal stenosis. Finally, plaque rupture or
superficial erosion leads to thrombosis and acute coronary
syndrome. Early forms of imaging using intracoronary
devices were able to assess atherosclerosis at the later stage
when the vascular morphology had changed. The newer
methods, such as the one reported by Hamilton et al. (1),
are geared toward imaging vessel wall injury, cellular traf-
ficking, and molecular alterations in the early and interme-
diate stages of atherosclerosis.
Noninvasive imaging for the detection of early athero-
sclerosis will depend on the development of tracers that are
targeted to early molecular changes observed in this process
and that can easily be administered intravenously. For this
approach to succeed, the imaging tracer (microbubbles,
paramagnetic agents, or radionuclide tracers) should be
present in high enough concentrations at the disease site to
be easily imaged over background signal. Certain conditions
related to the imaging tracer must be met for this to occur:
1) it must be targeted to a ligand that is selective for the
disease process; 2) it must have adequate access to the
ligand; 3) it must be retained long enough at the site of
interest for image acquisition; 4) it must clear rapidly from
the blood pool; and 5) it must be safe.
SIGNAL-TO-NOISE RATIO
In the study by Hamilton et al. (1), the segments that were
“positive” on intravascular imaging generally had signal
enhancement of 25% to 50% over background despite
upstream direct arterial injection of 8 mg of liposomes.
There are several reasons why the backscatter was relatively
low for a direct intracoronary imaging device. For ultra-
sound imaging, the signal-to-noise ratio is influenced by
tracer size and compressibility and by ultrasound power and
frequency. Liposomes are relatively small in size (several
hundred nanometers in diameter). Because signal from a
scatterer is related to the sixth power of the radius (3), if
microbubbles (several micrometers in diameter) instead of
liposomes with the same ligand affinity were used, the signal
would be much higher. Liposomes are also mostly filled
with fluid (4), making them less compressible than gas-filled
microbubbles. A further marked increase in signal is possi-
ble by oscillating compressible microbubbles at high acous-
tic power and/or lower ultrasound frequency. Therefore, the
use of intravenous microbubbles and state-of-the-art imag-
ing (harmonic, ultraharmonic, or power Doppler) (5) would
make it possible to get similar if not better results from
transthoracic echocardiography compared with those ob-
tained using intravascular ultrasound and intracoronary-
delivered liposomes.
SITE-SPECIFIC TARGETING
As stated previously, the signal-to-noise ratio for targeted
agents is partially determined by the site specificity and
affinity for the targeted molecule. It is also desirable to have
a relatively high density of the tracer at the disease site. For
the purposes of imaging inflammation, tracers can be
targeted to adhesion molecules expressed on the endothelial
surface, such as intercellular adhesion molecules (ICAMs),
vascular cell adhesion molecule-1, and selectins (6,7). This
approach was initially validated in vitro by Villanueva et al.
(8) with ICAM and used successfully by Hamilton et al. (1)
to define injury-induced atherosclerosis in coronary arteries
in vivo. It has also been used by us and by others for
assessing microvascular changes that occur early in inflam-
mation and angiogenesis (9–11). The potential advantage of
this approach is the ability to characterize very early disease
when endothelial injury or alteration has just begun. The
main limitation of this strategy is the potential lack of
specificity due to constitutive expression of these molecules,
especially ICAM-1 (6,7). Unfortunately, whether targeted
liposomes attach to non-diseased vessels was not evaluated
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by Hamilton et al. (1). The duration of adhesion molecule
expression may also be transitory and, for the immunoglob-
ulin family of receptors (ICAMs, vascular cell adhesion
molecule-1), may shift from endothelial to non-endothelial
locations (6).
Ultrasound imaging of targeted microbubbles in the
microcirculation has been possible because of the sensitivity
of the imaging techniques used (harmonic, ultra-harmonic,
and power Doppler) (5) and the relatively high number of
microbubbles retained. The hydrodynamic forces in the
great vessels and the larger segments of coronary arteries are
much higher, often exceeding 5 dynes·cm2. Whether
spherical bubbles can withstand these high rates despite
relatively high bond strength is not known. One way to
increase the binding of microbubbles is to make their shapes
more flexible and create crenations on their surfaces so that
they more closely resemble leukocytes (12). Another ap-
proach is to use various bubble populations that bind to
different adhesion molecules and potentially increase the
binding surface area and the range of binding affinities. This
approach was used successfully by Hamilton et al. (1).
Furthermore, because the vessel wall is echogenic, tissue
suppression techniques (such as ultraharmonic and power
Doppler) would be very useful in providing good signals
from the microbubbles.
THE ROLE OF VASO VASORUM
Whereas cell trafficking into the potential site of an athero-
sclerotic plaque occurs via the luminal surface of the vessel
early after injury, it occurs via the vasa vasorum in a
maturing plaque (13). Neovascularzation from the vasa
vasorum is seen in atherosclerosis both on the vessel
adventitia and within the plaque. These conduits facilitate
cell trafficking into the plaque and are therefore partly
responsible for the plaque “activity” (14). The hydrodynamic
forces are also more conducive to cell adhesion and migra-
tion compared with larger vessels with higher velocity flows.
Hamilton et al. (1) noted ultrasound signal not only from
the plaque but also from the surrounding adventitia, part of
which could have come from the vasa vasorum and other
newly formed vessels. In this regard it may also be valuable
to target molecules expressed during angiogenesis (9,10).
IMAGING PLAQUE CONTENT
Another approach could be targeting active cellular
plaque components, such as monocyte/macrophages or
T-lymphocytes. Microbubbles can be targeted to activated
leukocytes within the microcirculation (15); however, im-
aging leukocytes within the vessel wall is more likely to
succeed with diffusible tracers. Paramagnetic tracers, such as
iron oxide particles, have been found inside plaque macro-
phages on MRI (16).
Products released by leukocytes and activated smooth
muscle cells, such as cytokines, metalloproteinases, and
tissue factor, could also be targeted for imaging. It may also
be possible to assess plaque “activity” by measuring oxidative
changes within atherosclerotic lesions, such as the presence
of modified low-density lipoprotein (17), or other metabolic
alterations (18). Unlike imaging of plaque morphology
using earlier intracoronary approaches, imaging these tar-
gets could assist in determining plaque “activity” and pos-
sibly identify lesions likely to rupture. These non-invasive
approaches would be more practical than others that assess
thermal and metabolic plaque activity using intracardiac
devices.
CLINICAL IMPLICATIONS
Imaging atherosclerosis is now feasible as shown by Ham-
ilton et al. (1) and others (8,17,18). The techniques for this
purpose need further development before they can be used
noninvasively in humans. Whether characterization of cor-
onary atherosclerosis will provide incremental value in
individual patients over standard risk factor assessment in
conjunction with currently available biomarkers (such as
high-sensitivity C-reactive protein) or those likely to
emerge from proteomic profiling of blood from large patient
population remains to be determined. These non-invasive
imaging approaches could, however, be used to understand
the pathobiology of atherosclerosis in humans. They could
also be valuable in measuring the efficacy of different
therapeutic interventions. Precise quantification of the effect
of interventions on plaque “activity” rather than measure-
ment of clinical outcomes alone could decrease the number
of patients required in clinical trials that contribute to the
high cost of drug development and thus health care,
something that even this country can ill afford in the long
run.
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